BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holstein SA, Suman VJ, McCarthy PL. Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials? Curr Hematol Malig Rep 2019;14:31-8. [PMID: 30661162 DOI: 10.1007/s11899-019-0495-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 He J, Berringer H, Heeg B, Ruan H, Kampfenkel T, Dwarakanathan HR, Johnston S, Mendes J, Lam A, Bathija S, Mackay E. Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma. Adv Ther 2022. [PMID: 35876974 DOI: 10.1007/s12325-022-02226-x] [Reference Citation Analysis]
2 Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, Hoering A, Richardson PG, Schwartz EI, Reiman A, Lentzsch S, McCarthy PL, Jagannath S, Yee AJ, Little RF, Raje NS. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J 2022;12:98. [PMID: 35768410 DOI: 10.1038/s41408-022-00695-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. Am J Hematol 2021;96:690-7. [PMID: 33735453 DOI: 10.1002/ajh.26166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Elnair RA, Holstein SA. Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. Drugs 2021;81:825-40. [PMID: 33871818 DOI: 10.1007/s40265-021-01514-0] [Reference Citation Analysis]
5 Hanafi HHW, Husin A, Yaacob NM, Abdullah AD. Relapsed/Progressive Disease and Its Prognostic Factors among Multiple Myeloma Patients Receiving Novel Agent Treatment in North East Peninsular Malaysia: A Single Centre Experience. Malays J Med Sci 2020;27:62-77. [PMID: 33154703 DOI: 10.21315/mjms2020.27.5.7] [Reference Citation Analysis]
6 Zhang M, Zhao X, Cai X, Wang P, Yu M, Wei Z. Knockdown of long non-coding RNA plasmacytoma variant translocation 1 inhibits cell proliferation while promotes cell apoptosis via regulating miR-486-mediated CDK4 and BCAS2 in multiple myeloma. Ir J Med Sci 2020;189:825-34. [PMID: 31900844 DOI: 10.1007/s11845-019-02165-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 2020;26:e7-e15. [PMID: 31526843 DOI: 10.1016/j.bbmt.2019.09.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]